367 related articles for article (PubMed ID: 34771580)
1. Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies.
Jacob A; Raj R; Allison DB; Myint ZW
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771580
[TBL] [Abstract][Full Text] [Related]
2. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer.
Zhao J; Ning S; Lou W; Yang JC; Armstrong CM; Lombard AP; D'Abronzo LS; Evans CP; Gao AC; Liu C
Mol Cancer Ther; 2020 Aug; 19(8):1708-1718. PubMed ID: 32430485
[TBL] [Abstract][Full Text] [Related]
3. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
Sperger JM; Emamekhoo H; McKay RR; Stahlfeld CN; Singh A; Chen XE; Kwak L; Gilsdorf CS; Wolfe SK; Wei XX; Silver R; Zhang Z; Morris MJ; Bubley G; Feng FY; Scher HI; Rathkopf D; Dehm SM; Choueiri TK; Halabi S; Armstrong AJ; Wyatt AW; Taplin ME; Zhao SG; Lang JM
J Clin Oncol; 2021 Sep; 39(26):2926-2937. PubMed ID: 34197212
[TBL] [Abstract][Full Text] [Related]
4. Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit.
Smith BN; Mishra R; Billet S; Placencio-Hickok VR; Kim M; Zhang L; Duong F; Madhav A; Scher K; Moldawer N; Oppenheim A; Angara B; You S; Tighiouart M; Posadas EM; Bhowmick NA
Mol Ther; 2023 Jan; 31(1):78-89. PubMed ID: 36045587
[TBL] [Abstract][Full Text] [Related]
5. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
6. TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer.
Yoshida S; Kajiwara D; Seki M; Tayama M; Tanaka Y; Mizutani H; Fujita R; Yamamura K; Okajima S; Asai M; Minamiguchi K
Mol Oncol; 2024 Apr; ():. PubMed ID: 38600681
[TBL] [Abstract][Full Text] [Related]
7. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
Zhu Y; Dalrymple SL; Coleman I; Zheng SL; Xu J; Hooper JE; Antonarakis ES; De Marzo AM; Meeker AK; Nelson PS; Isaacs WB; Denmeade SR; Luo J; Brennen WN; Isaacs JT
Oncogene; 2020 Nov; 39(45):6935-6949. PubMed ID: 32989253
[TBL] [Abstract][Full Text] [Related]
8. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
9. Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients.
Maillet D; Allioli N; Peron J; Plesa A; Decaussin-Petrucci M; Tartas S; Ruffion A; Crouzet S; Rimokh R; Gillet PG; Freyer G; Vlaeminck-Guillem V
Eur Urol Oncol; 2021 Aug; 4(4):609-617. PubMed ID: 31676281
[TBL] [Abstract][Full Text] [Related]
10. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
[TBL] [Abstract][Full Text] [Related]
12. Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.
Crona DJ; Whang YE
Cancers (Basel); 2017 Jun; 9(6):. PubMed ID: 28604629
[TBL] [Abstract][Full Text] [Related]
13. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.
Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ
Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568
[TBL] [Abstract][Full Text] [Related]
14. ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.
Cai L; Tsai YH; Wang P; Wang J; Li D; Fan H; Zhao Y; Bareja R; Lu R; Wilson EM; Sboner A; Whang YE; Zheng D; Parker JS; Earp HS; Wang GG
Mol Cell; 2018 Oct; 72(2):341-354.e6. PubMed ID: 30270106
[TBL] [Abstract][Full Text] [Related]
15. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
16. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
17. AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost-Saving Analysis.
Pacheco-Orozco RA; Montealegre-Páez L; Cayol F; Martínez-Gregorio H; Oliver J; Frecha C; Vaca-Paniagua F; Perdomo S
Oncologist; 2020 Dec; 25(12):e1990-e1995. PubMed ID: 32721059
[TBL] [Abstract][Full Text] [Related]
18. ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling.
Liu C; Armstrong CM; Ning S; Yang JC; Lou W; Lombard AP; Zhao J; Wu CY; Yu A; Evans CP; Tepper CG; Li PK; Gao AC
Oncogene; 2021 Sep; 40(35):5379-5392. PubMed ID: 34272475
[TBL] [Abstract][Full Text] [Related]
19. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Antonarakis ES; Lu C; Wang H; Luber B; Nakazawa M; Roeser JC; Chen Y; Mohammad TA; Chen Y; Fedor HL; Lotan TL; Zheng Q; De Marzo AM; Isaacs JT; Isaacs WB; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
N Engl J Med; 2014 Sep; 371(11):1028-38. PubMed ID: 25184630
[TBL] [Abstract][Full Text] [Related]
20. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]